Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France

Frederique Penault-Llorca; Anne Vincent-Salomon; Jean-Pierre Bellocq; Marie-Christine Matthieu; Gaetan-Mac Grogan; Isabelle Treilleux; Francette Ettore; Sophie Laberge-Le Couteulx; Brigitte Sigal; Jerome Couturier; Magali Lacroix-Triki; Martine Antoine; Andre Balaton; Marie-Christine Baranzelli; Valerie Becette; Cecile Blanc-Fournier; Frederic Bibeau; Eva Brabencova; Sabrina Croce; Viviana Fridman; Pascal Genin; Jean-Pierre Ghnassia; Jocelyne Jacquemier; Bruno Poulet; Pascal Roger; Christine Sagan; Patrick Tas; Martine Trassard; Veronique Verriele; Laurent Arnould; GEFPICS

doi:10.1016/j.annpat.2010.07.001

Retour

Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France

Article de revue

Avec comité de lecture

Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France

Frederique Penault-Llorca, Anne Vincent-Salomon, Jean-Pierre Bellocq, Marie-Christine Matthieu, Gaetan-Mac Grogan, Isabelle Treilleux, Francette Ettore, Sophie Laberge-Le Couteulx, Brigitte Sigal, Jerome Couturier, …

Annales de pathologie, Vol.30(5), pp.357-373

01/10/2010

DOI: https://doi.org/10.1016/j.annpat.2010.07.001

PMID: 21055523

Résumé

Life Sciences & Biomedicine

Pathology

Science & Technology

In Europe, patients who may benefit from an HER2 targeted drug are currently selected by immunohistochemistry (IHC). In situ hybridization (ISH) techniques should be used for complementary assessment of ambiguous 2+ IHC cases and for the calibration of the IHC technique. Eligibility to an HER2 target treatment is defined by an HER2 positive status being IHC test 3+ or 2+ amplified. Reliable detection of HER2 status is essential to the appropriate usage of HER2 targeted drugs because its specificity is limited to tumors overexpressing HER2. It is essential that the IHC evaluation of the HER2 status of a mammary carcinoma is optimized and reliable. This GEFPICS' guidelines look over the different steps of the IHC technique, the controls and, the rules for interpretation. Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs). (C) 2010 Elsevier Masson SAS. All rights reserved.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
Créateurs - sans rôle: Frederique Penault-Llorca - Ctr Jean Perrin, Dept Pathol, F-63011 Clermont Ferrand, France
Anne Vincent-Salomon - Inst Curie, Serv Anat Pathol, F-75248 Paris 05, France
Jean-Pierre Bellocq - Hop Hautepierre, Serv Anat Pathol, F-67098 Strasbourg, France
Marie-Christine Matthieu - Inst Gustave Roussy, Dept Biol & Pathol Med, F-94805 Villejuif, France
Gaetan-Mac Grogan - Inst Bergonie, Serv Anat & Cytol Pathol, F-33076 Bordeaux, France
Isabelle Treilleux - Ctr Leon Berard, Serv Anat & Cytol Pathol, F-69373 Lyon 8, France
Francette Ettore - Ctr Antoine Lacassagne, Serv Anat Pathol, F-06189 Nice 2, France
Sophie Laberge-Le Couteulx - CRLCC Henri Becquerel, Serv Anat & Cytol Pathol, F-76000 Rouen, France
Brigitte Sigal - Inst Curie, Serv Anat Pathol, F-75248 Paris 05, France
Jerome Couturier - Inst Curie, Serv Anat Pathol, F-75248 Paris 05, France
Magali Lacroix-Triki - Inst Claudius Regaud, Serv Anat Pathol, F-31052 Toulouse, France
Martine Antoine - Hop Tenon, Serv Cent Anat Pathol, F-75970 Paris, France
Andre Balaton - Ctr Pathol, F-91570 Bievres, France
Marie-Christine Baranzelli - Ctr Oscar Lambret, Serv Anat Pathol, F-59020 Lille, France
Valerie Becette - Ctr Rene Huguenin, Serv Anat & Cytol Pathol, F-92210 St Cloud, France
Cecile Blanc-Fournier - Ctr Francois Baclesse, Serv Anat & Cytol Pathol, F-14021 Caen, France
Frederic Bibeau - Ctr Val Aurelle, Serv Anat Pathol, F-34298 Montpellier 5, France
Eva Brabencova - Inst Jean Godinot, Serv Anat & Cytol Pathol, F-51100 Reims, France
Sabrina Croce - Hop Hautepierre, Serv Anat Pathol, F-67098 Strasbourg, France
Viviana Fridman - Hop La Citadelle, Serv Anat & Cytol Pathol, B-4000 Liege, Belgium
Pascal Genin - Ctr Alexis Vautrin, Serv Anat Pathol, F-54511 Vandoeuvre Les Nancy, France
Jean-Pierre Ghnassia - Ctr Paul Strauss, Serv Anat Pathol, F-67085 Strasbourg, France
Jocelyne Jacquemier - Inst J Paoli I Calmettes, Serv Anat Pathol, F-13027 Marseille 9, France
Bruno Poulet - Ctr Pathol, F-75016 Paris 16, France
Pascal Roger - Univ Caremeau, Grp Hosp, F-30029 Nimes 09, France
Christine Sagan - Hop G & R Laennec, Serv Anat Pathol, F-44800 St Herblain, France
Patrick Tas - Université Rennes 1
Martine Trassard - Ctr Rene Huguenin, Serv Anat & Cytol Pathol, F-92210 St Cloud, France
Veronique Verriele - Ctr Paul Papin, Serv Anat Pathol, F-49033 Angers, France
Laurent Arnould - Ctr GF Leclerc, Serv Anat Pathol, F-21034 Dijon, France
GEFPICS
Détails de publication: Annales de pathologie, Vol.30(5), pp.357-373
Éditeur: Elsevier
Nombre de pages: 17
Identifiants: 99162571209311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: French
Type de ressource: Journal article